REST EZ Inc. (RTEZ) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1398 WEST MASON HOLLOW DRIVE RIVERTON, UT 84065 |
| State of Incorp. | WY |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 MRQ | 3/31/2023 | 3/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | |||
| Cash and cash equivalents | 0 | 0 | |||
| Inventory, net of allowances, customer advances and progress billings | 3 | 3 | |||
| Inventory | 3 | 3 | |||
| Other undisclosed current assets | 405 | ||||
| Total current assets: | 3 | 408 | |||
| Noncurrent Assets | |||||
| TOTAL ASSETS: | 3 | 408 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 42 | ||||
| Accounts payable | 0 | ||||
| Accrued liabilities | 42 | ||||
| Due to related parties | ✕ | 118 | |||
| Other undisclosed current liabilities | 131 | 42 | |||
| Total current liabilities: | 173 | 160 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 173 | 160 | |||
| Equity | |||||
| Equity, attributable to parent | (171) | 248 | |||
| Common stock | 20 | 20 | |||
| Additional paid in capital | 122 | 111 | |||
| Retained earnings (accumulated deficit) | (312) | 117 | |||
| Total equity: | (171) | 248 | |||
| TOTAL LIABILITIES AND EQUITY: | 3 | 408 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 TTM | 3/31/2023 | 3/31/2022 | ||
|---|---|---|---|---|
| Revenues | 519 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (269) | |||
| Gross profit: | 250 | |||
| Operating expenses | (418) | (27) | ||
| Operating income (loss): | (418) | 224 | ||
| Nonoperating expense (Other Nonoperating expense) | (10) | (10) | ||
| Interest and debt expense | (10) | (10) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (439) | 204 | ||
| Other undisclosed income from continuing operations before income taxes | 10 | 10 | ||
| Income (loss) from continuing operations before income taxes: | (429) | 214 | ||
| Income tax expense | (42) | |||
| Income (loss) from continuing operations: | (429) | 172 | ||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | 172 | |
| Net income (loss) available to common stockholders, diluted: | (429) | 172 | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 TTM | 3/31/2023 | 3/31/2022 | ||
|---|---|---|---|---|
| Net income (loss): | (429) | 172 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (429) | 172 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.